🎉 Orders $200+ Get Free Domestic Shipping!

Tirzy

Tirzepatide is a cutting-edge research peptide designed to activate both GIP and GLP-1 receptors—two key regulators of insulin and glucose metabolism. By mimicking the body’s natural incretin hormones, Tirzepatide enhances insulin secretion, improves insulin sensitivity, and helps regulate appetite and body weight.

It has gained significant attention in the scientific community for its potential role in addressing metabolic disorders such as type 2 diabetes, obesity, and non-alcoholic fatty liver disease. Research models have shown impressive reductions in blood glucose levels and sustained weight loss, often outperforming GLP-1 agonists alone.

Tirzepatide is being actively investigated for its multi-pathway benefits, including effects on cardiovascular health and inflammatory markers. While promising, it remains strictly for laboratory research use and is not approved for human consumption or clinical therapy. For qualified professionals exploring metabolic modulation, Tirzepatide represents a powerful tool in advancing understanding of dual incretin mechanisms.

Peptides will arrive in a lyophilized (powder) form for maximum stability

$124.97

Quantity

⚠️ Legal Disclaimer

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro laboratory research only. In-vitro studies (Latin: “in glass”) are performed outside of living organisms. These products are not medicines or drugs, and they have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. Under no circumstances should these products be introduced into the human or animal body, whether by injection, ingestion, topical application, or any other route. Bodily introduction is strictly prohibited by law.

Subscribe to our newsletter

Want to get 15% OFF site-wide plus a FREE keychain? Subscribe to our newsletter to claim this offer!

Please wait...

Thank you for subscribing!